Remeditex was formed to invest in high quality, innovative, early stage projects that are judged to have commercialization potential.
Business Model:
Revenue: $7.3M
Employees: 2-10
Address: 2101 Cedar Springs Rd
City: Dallas
State: TX
Zip: 75201
Country: US
Remeditex was formed to invest in high quality, innovative, early stage projects that are judged to have commercialization potential. The goal is to help investigators establish the commercial viability of their research making it attractive to traditional investors.
Contact Phone:
+12145062662
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2011 | Peloton Therapeutics | Series A | 18M |
3/2012 | Bellicum Pharmaceuticals | Series B | 20M |
11/2015 | Viridian Therapeutics | Series C | 0 |
4/2012 | Viridian Therapeutics | Series B | 20M |
11/2015 | VYNE Therapeutics | Series B | 45M |
5/2015 | VYNE Therapeutics | Series A | 14.3M |
6/2014 | Viridian Therapeutics | Series B | 7M |
7/2017 | VYNE Therapeutics | Series C | 50.5M |
9/2017 | Rodin Therapeutics | Series C | 0 |
6/2019 | Soliton | Post-IPO Equity | 0 |
1/2014 | Bellicum Pharmaceuticals | Series B | 14.7M |
2/2012 | Apollo Endosurgery | Series B | 0 |
9/2012 | Bi02 Medical | Series C | 0 |
3/2009 | BiOptix Diagnostics | Series A | 3M |
12/2015 | Navitor Pharmaceuticals | Series B | 33M |
9/2016 | Peloton Therapeutics | Series D | 0 |
2/2015 | Viridian Therapeutics | Series B | 0 |
6/2019 | Soliton | Post-IPO Equity | 0 |
9/2017 | Rodin Therapeutics | Series C | 0 |
7/2017 | VYNE Therapeutics | Series C | 0 |
9/2016 | Peloton Therapeutics | Series D | 0 |
12/2015 | Navitor Pharmaceuticals | Series B | 0 |
11/2015 | Viridian Therapeutics | Series C | 0 |
11/2015 | VYNE Therapeutics | Series B | 0 |
5/2015 | VYNE Therapeutics | Series A | 0 |
2/2015 | Viridian Therapeutics | Series B | 0 |
6/2014 | Viridian Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|